-
Study Unveils Rare Cannabinoid As Promising Hope For Alzheimer's, Parkinson's & Huntington's Treatment
Thursday, June 1, 2023 - 3:47pm | 452Read More...The study focused on the potential of rare cannabinoids in the treatment of neurodegenerative diseases like Alzheimer's. According to the researchers behind the study, this breakthrough research opens new avenues for addressing the unmet medical needs of patients with conditions like Alzheimer...
-
DEA Sued By Rhode Island Lab Over 'Foot Dragging' On Marijuana Pharmaceutical Licensing, Here's What We Know So Far
Wednesday, April 13, 2022 - 7:51am | 668Read More...Two Rhode Island cannabinoid research laboratories are suing the DEA for standing in the way of what they consider to be the crucial development of pharmaceutical-grade cannabis products for use in clinical trials for the treatment of Multiple Sclerosis and...
-
Stealth Bio's SBT-272 Shows Encouraging Action In Huntington's Disease Animal Model
Thursday, March 31, 2022 - 8:23am | 264Read More...Stealth BioTherapeutics Corp (NASDAQ: MITO) announced the presentation of new SBT-272 preclinical data and dosing of the first subject in its Phase 1 trial of SBT-272. The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington's...
-
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
Wednesday, January 5, 2022 - 7:33am | 246Read More...Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period. Annexon is developing ANX005, its lead monoclonal antibody candidate, for a range of complement-...
-
UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial
Thursday, December 16, 2021 - 2:10pm | 376Read More...UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease. AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes (vg). There have...
-
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
Wednesday, December 8, 2021 - 7:26am | 372Read More...Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with Huntington's disease (HD). The selective vesicular monoamine transporter 2 (VMAT2) inhibitor is being investigated...
-
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
Tuesday, September 7, 2021 - 6:55am | 195Read More...Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark Therapeutics is a part of Roche Holdings AG (OTC: RHHBY). Under the deal, Spark Therapeutics has the option to license...
-
DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged
Thursday, May 27, 2021 - 11:48am | 202Read More...The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial evaluating UniQure NV's (NASDAQ: QURE) AMT-130 for Huntington's disease. The DSMB recommended continued...
-
Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy
Monday, April 26, 2021 - 9:32am | 323Read More...Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidate for Huntington's disease (HD). The agency has confirmed that...
-
Wave Life Sciences Stock Plunges After Antisense Oligonucleotide Candidates Disappoint In Huntington's Disease Study
Tuesday, March 30, 2021 - 5:38am | 421Read More...Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happened: WVE-120102 failed to separate from the placebo with no...
-
Ionis Pharma Stock Is Trading Lower After Roche Drops Huntington's Disease Trial With Tominersen
Tuesday, March 23, 2021 - 6:54am | 297Read More...Roche Holdings AG (OTCMKTS: RHHBY) has halted dosing for its Phase 3 study of tominersen, an antisense drug targeting the huntingtin protein and a mutant variant. Roche is calling off the study after an independent data committee “made its recommendation based on the...
-
No Safety Concerns Observed In Uniqure's Early-Stage Huntington's Gene Therapy Study, DSMB Says
Monday, February 8, 2021 - 10:57am | 245Read More...Independent Data Safety Monitoring Board (DSMB) has reviewed the six-month safety data from the first two enrolled patients and 90-day safety data from the next two enrolled patients from Phase 1/2 trial evaluating Uniqure N.V.'s (NASDAQ: QURE) AMT-130...
-
Janney: Buy The Dip In Uniqure
Tuesday, March 20, 2018 - 11:39am | 519Read More...Uniqure NV (NASDAQ: QURE) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip. The Analyst Janney analyst Yun Zhong reiterated a Buy rating on the shares of Uniqure and increased the fair value estimate from $25 to $30....
